Evidence map›Paper›PMID 31916228›Full record

ArticleJournal of nephrology2020

Tubulointerstitial damage and interstitial immune cell phenotypes are useful predictors for renal survival and relapse in antineutrophil cytoplasmic antibody-associated vasculitis.

Laura Bitton, Cyrille Vandenbussche, Nicolas Wayolle, Jean-Baptiste Gibier, Carole Cordonnier, Jérôme Verine, Sarah Humez, Pierre Bataille, Rémi Lenain, Nassima Ramdane and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 1 country.

Laura BittonPathology Department, AP-HP, Hôpital Tenon, 75020, Paris, France.
Cyrille VandenbusscheNephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.
Nicolas WayolleNephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.
Jean-Baptiste GibierPathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France.
Carole CordonnierPathology Department, Amiens University Hospital, 80054, Amiens, France.
Jérôme VerineHôpital Saint-Louis Pathology Department, AP-HP, 75010, Paris, France.
Sarah HumezPathology Department, CNRS, Institut Pasteur de Lille, UMR 8161-M3T "Mechanisms of Tumorigenesis and Targeted Therapies", Univ. Lille, CHU Lille, 59000, Lille, France.
Pierre BatailleNephrology Department, Hospital of Boulogne-Sur-Mer, 62200, Boulogne-sur-Mer, France.
Rémi LenainEA 2694-Santé Publique : épidémiologie Et qualité Des Soins, Univ. Lille, CHU Lille, 59000, Lille, France.
Nassima RamdaneEA 2694-Santé Publique : épidémiologie Et qualité Des Soins, Univ. Lille, CHU Lille, 59000, Lille, France.
Raymond AzarNephrology Department, Hospital of Dunkerque, 59385, Dunkerque, France.
Evelyne Mac NamaraNephrology Department, Hospital of Béthune-Beuvry, 62408, Béthune, France.
Pierre-Yves HatronInternal Medicine Department, Univ. Lille, CHU Lille, 59000, Lille, France.
Claude-Alain MauragePathology Department, Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert Research Center, Team "Alzheimer & Tauopathies", 59000, Lille, France.
Michael PerraisPathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France.
Marie FrimatNephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.
Philippe VanhilleNephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.
François GlowackiNephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.
David BuobPathology Department, AP-HP, Hôpital Tenon, 75020, Paris, France.
Marie-Christine CopinPathology Department, CNRS, Institut Pasteur de Lille, UMR 8161-M3T "Mechanisms of Tumorigenesis and Targeted Therapies", Univ. Lille, CHU Lille, 59000, Lille, France.
Thomas QuéméneurNephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.
Viviane GnemmiPathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France. viviane.gnemmi@univ-lille.fr.ORCID http://orcid.org/0000-0001-7403-4607
Université de Lille · FRInserm · FRCentre Hospitalier de Valenciennes · FRCentre National de la Recherche Scientifique · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier de Béthune · FRCentre Hospitalier Universitaire Amiens-Picardie · FRUniversité d'été de Boulogne-sur-Mer · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aims of this study were to determine whether tubulointerstitial damage in the form of interstitial fibrosis/tubular atrophy and total interstitial inflammation predicted progression to end stage renal disease (ESRD) and/or renal relapse (RR) in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). One hundred thirteen patients with AAV from six French centers with an index biopsy performed between 2003 and 2013 were included. Histological assessments using the AAV glomerular classification and the kidney allograft Banff classification were performed on pathological review. Biopsy tissues were also investigated by CD3, CD20, CD68, CD163, FOXP3 and RORγt immunohistochemical staining. Competing risks models were calculated. Of the 113 patients, 26 (23.0%) died during follow-up and 29 (25.6%) developed ESRD. Among the 94 patients who achieved remission by the end of induction therapy without developing ESRD, 26 (27.6%) experienced RR. The two independent prognostic factors for ESRD were the estimated glomerular filtration rate at presentation (HR 0.35; 95% CI 0.23-0.51; P < 0.0001) and IF/TA > 25% (HR 2.27; 95% CI 1.18-4.37; P = 0.014). When the distribution of interstitial immune cell phenotypes was included in a second multivariable model, the organization of lymphocytic infiltrates was also an independent predictor of ESRD (HR 2.86; 95% CI 1.35-6.1, P = 0.006). The independent risk factors for RR were a higher CD3/CD20 ratio (HR 1.39; 95% CI 1.05-1.85; P = 0.02) and the presence of RORγt positive cells (HR 2.70; 95% CI 1.11-6.54; P = 0.02). Our results highlight the prognostic value of initial histological evaluations in AAV. Measurements of tubulointerstitial damage and interstitial immune cell phenotype distributions should be considered to improve risk assessments for ESRD and RR.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisKidney Failure, ChronicAntibodies, Antineutrophil CytoplasmicHumansKidneyKidney TubulesPhenotypeRecurrenceRetrospective StudiesAntibodies, Antineutrophil CytoplasmicANCA-associated vasculitisFibrosisInterstitial lymphocytic organizationMacrophageRenal relapseTh17

Identifiers

PMID31916228
OpenAlexW2999664517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.